Safety and Efficacy of Alefacept in Elderly Patients and Other Special Populations
November 2005 | Volume 4 | Issue 6 | Original Article | 718 | Copyright © November 2005
Alice B. Gottlieb MD PhD, Wolf-Henning Boehncke MD, Mohamed Darif PhD
Background: The safety of biologic agents for psoriasis treatment is of particular importance in patient groups at higher
risk for adverse events. We assessed the safety and efficacy of alefacept in elderly, obese, and diabetic patients with
moderate to severe chronic plaque psoriasis by integrating data from phase 2 and 3 clinical studies and their extensions.
Observations: Ninety-nine elderly, 652 obese, and 122 diabetic patients received at least 1 course of alefacept. In each
cohort, accidental injury, headache, and pharyngitis were among the most common adverse events; infections were primarily
common colds; and malignancies were mostly skin carcinomas. No opportunistic infections were reported. Safety
was maintained over repeated courses. The safety profile of alefacept in each cohort was consistent with that of the
overall population; however, additional data are needed to confirm our findings in the elderly and diabetic subgroups
in the later courses due to the limited sample sizes. In course 1, 24% to 33% of patients achieved 75% or greater
improvement in Psoriasis Area and Severity Index (PASI) at any time, with further enhancement of benefit with subsequent
courses (eg, course 3, 41% to 58%).
Conclusions: Alefacept was well-tolerated and effective in elderly, obese, and diabetic patients with psoriasis.